Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc (COCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus GlobeNewswire - Thu Dec 18, 7:00AM CST

Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference GlobeNewswire - Mon Dec 1, 7:00AM CST

BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules GlobeNewswire - Thu Oct 30, 7:00AM CDT

Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $ 1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program GlobeNewswire - Mon Oct 27, 7:00AM CDT

BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR)...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference GlobeNewswire - Thu Oct 2, 7:00AM CDT

BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire - Mon Sep 15, 3:30PM CDT

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE)...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire - Fri Sep 12, 8:43AM CDT

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE)...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference GlobeNewswire - Fri Sep 12, 7:00AM CDT

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment GlobeNewswire - Mon Sep 8, 7:00AM CDT

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused...

COCP : 0.9700 (-0.42%)
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference GlobeNewswire - Wed Sep 3, 7:00AM CDT

BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company...

COCP : 0.9700 (-0.42%)

Barchart Exclusives

This International Pharma Stock Just Hit 5-Year Highs Barchart - Fri Dec 26, 9:45AM CST
Teva Pharmaceutical (TEVA) is trading at new 5-year highs. Shares are up more than 40% over the past year. The stock has strong technical momentum, maintaining a 100% “Buy” opinion from Barchart. TEVA offers international diversification and is favored by both Wall Street and individual investors. Today’s Featured Stock Valued... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot